Recursion Pharmaceuticals (NASDAQ:RXRX) Director Namandje Bumpus Sells 4,386 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Namandje Bumpus sold 4,386 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $3.54, for a total value of $15,526.44. Following the transaction, the director directly owned 43,171 shares in the company, valued at approximately $152,825.34. The trade was a 9.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Price Performance

RXRX opened at $3.80 on Friday. The stock’s 50-day moving average price is $3.30 and its 200 day moving average price is $3.82. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.77 and a 12-month high of $7.18. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -3.17 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm had revenue of $6.47 million for the quarter, compared to analyst estimates of $15.78 million. During the same quarter in the prior year, the company earned ($0.50) EPS. Recursion Pharmaceuticals’s revenue was down 56.8% on a year-over-year basis. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.02 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Recursion Pharmaceuticals by 18.6% in the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after acquiring an additional 7,407,606 shares during the last quarter. ARK Investment Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 11.2% in the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after acquiring an additional 3,771,357 shares during the last quarter. State Street Corp increased its holdings in shares of Recursion Pharmaceuticals by 38.7% in the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after acquiring an additional 7,064,963 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 13.6% in the 4th quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company’s stock valued at $44,731,000 after acquiring an additional 1,310,695 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $23,473,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Bank of America decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. JPMorgan Chase & Co. decreased their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Wall Street Zen lowered Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.10.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.